English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  The Tigecycline Evaluation and Surveillance Trial (T.E.S.T) is a global antimicrobial surveillance study of both gram-positive and gram-negative organisms. This report presents data on antimicrobial susceptibility among organisms collected in Mexico between 2005 and 2012 as part of T.E.S.T., and compares rates between 2005–2007 and 2008–2012.    Method  Each center in Mexico submitted at least 200 isolates per collection year; including 65 gram-positive isolates and 135 gram-negative isolates. Minimum inhibitory concentrations (MICs) were determined using Clinical Laboratory Standards Institute (CLSI) broth microdilution methodology and antimicrobial susceptibility was established using the 2013 CLSI-approved breakpoints. For tigecycline US Food and Drug Administration (FDA) breakpoints were applied. Isolates of  E. coli  and  K. pneumoniae  with a MIC for ceftriaxone of >1 mg/L were screened for ESBL production using the phenotypic confirmatory disk test according to CLSI guidelines.    Results  The rates of some key resistant phenotypes changed during this study: vancomycin resistance among  Enterococcus faecium  decreased from 28.6 % in 2005–2007 to 19.1 % in 2008–2012, while β-lactamase production among  Haemophilus influenzae  decreased from 37.6 to 18.9 %. Conversely, methicillin-resistant  Staphylococcus aureus  increased from 38.1 to 47.9 %, meropenem-resistant  Acinetobacter  spp. increased from 17.7 to 33.0 % and multidrug-resistant  Acinetobacter  spp. increased from 25.6 to 49.7 %. The prevalence of other resistant pathogens was stable over the study period, including extended-spectrum β-lactamase-positive  Escherichia coli  (39.0 %) and  Klebsiella pneumoniae  (25.0 %). The activity of tigecycline was maintained across the study years with MIC 90 s of ≤2 mg/L against  Enterococcus  spp.,  S. aureus ,  Streptococcus agalactiae ,  Streptococcus pneumoniae ,  Enterobacter  spp.,  E. coli ,  K. pneumoniae ,  Klebsiella oxytoca ,  Serratia marcescens ,  H. influenzae , and  Acinetobacter  spp. All gram-positive organisms were susceptible to tigecycline and susceptibility among gram-negatives ranged from 95.0 % for  K. pneumoniae  to 99.7 % for  E. coli .    Conclusion  Antimicrobial resistance continues to be high in Mexico. Tigecycline was active against gram-positive and gram-negative organisms, including resistant phenotypes, collected during the study.

annals of clinical microbiology and antimicrobials

Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial